Brazilian guidelines for the treatment of outpatients with suspected or confirmed COVID-19. A joint guideline of the Brazilian Association of Emergency Medicine (ABRAMEDE), Brazilian Medical Association (AMB), Brazilian Society of Angiology and Vascular Surgery (SBACV), Brazilian Society of Geriatrics and Gerontology (SBGG), Brazilian Society of Infectious Diseases (SBI), Brazilian Society of Family and Community Medicine (SBFMC), and Brazilian Thoracic Society (SBPT)

Imagem de Miniatura
Arquivos
art_FALAVIGNA_Brazilian_guidelines_for_the_treatment_of_outpatients_with_2022.PDF (529.74 KB)
Citações na Scopus
2
Tipo de produção
article
Data de publicação
2022
DOI
SciELO
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
ELSEVIER BRAZIL
Autores
FALAVIGNA, Maicon
BELLI, Karlyse Claudino
BARBOSA, Alexandre Naime
ZAVASCKI, Alexandre Prehn
SANTANA, Christiane Machado
STEIN, Cinara
GRAF, Debora Dalmas
CADEGIANI, Flavio Adsuara
GUIMARAES, Helio Penna
Citação
BRAZILIAN JOURNAL OF INFECTIOUS DISEASES, v.26, n.2, article ID 102347, 10p, 2022
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Several therapies have been used or proposed for the treatment of COVID-19, although their effectiveness and safety have not been properly evaluated. The purpose of this document is to provide recommendations to support decisions about the drug treatment of outpatients with COVID-19 in Brazil.Methods: A panel consisting of experts from different clinical fields, representatives of the Brazilian Ministry of Health, and methodologists (37 members in total) was responsible for preparing these guidelines. A rapid guideline development method was used, based on the adoption and/or adaptation of recommendations from existing international guidelines combined with additional structured searches for primary studies and new recommendations whenever necessary (GRADE-ADOLOPMENT). The rating of quality of evidence and the drafting of recommendations followed the GRADE method.Results: Ten technologies were evaluated, and 10 recommendations were prepared. Recommendations were made against the use of anticoagulants, azithromycin, budesonide, colchicine, corticosteroids, hydroxychloroquine/chloroquine alone or combined with azithromycin, ivermectin, nitazoxanide, and convalescent plasma. It was not possible to make a recommendation regarding the use of monoclonal antibodies in outpatients, as their benefit is uncertain and their cost is high, with limitations of availability and implementation.Conclusion: To date, few therapies have demonstrated effectiveness in the treatment of outpatients with COVID-19. Recommendations are restricted to what should not be used, in order to provide the best treatment according to the principles of evidence-based medicine and to promote resource savings by aboiding ineffective treatments. (c) 2022 Sociedade Brasileira de Infectologia.
Palavras-chave
COVID-19, COVID-19 drug treatment, Guideline, SARS-CoV-2, Brazil, GRADE
URI
https://observatorio.fm.usp.br/handle/OPI/48348
Referências
  1. Akl EA, 2021, J CLIN EPIDEMIOL, V129, P1, DOI 10.1016/j.jclinepi.2020.09.037
  2. amb, DIRETRIZES COVID 19
  3. [Anonymous], 2022, WEEKLY EPIDEMIOLOGIC
  4. [Anonymous], 2022, PAINEL CORONAVRUS
  5. astrazeneca, AZD7442 PROVENT PHAS
  6. Azoulay E, 2020, CRIT CARE, V24, DOI 10.1186/s13054-020-03194-w
  7. Bernal AJ, 2022, NEW ENGL J MED, V386, P509, DOI 10.1056/NEJMoa2116044
  8. Berwanger O, 2022, LANCET GLOB HEALTH, V10, pE2, DOI 10.1016/S2214-109X(21)00501-5
  9. Bhimraj A, IDSA GUIDELINES TREA
  10. Bhimraj Adarsh, 2020, Clin Infect Dis, DOI 10.1093/cid/ciaa478
  11. Brazilian Clinical Research Institute, AP PROPHYLAXIS THROM
  12. Chalmers JD, 2021, EUR RESPIR J, V57, DOI 10.1183/13993003.00048-2021
  13. conitec, DIRETRIZES BRASILEIR
  14. covid19evidence, NATL COVID 19 CLIN E
  15. Falavigna Maicon, 2020, Rev. bras. ter. intensiva, V32, P166, DOI 10.5935/0103-507x.20200039
  16. Guimaraes PO, 2021, NEW ENGL J MED, V385, P406, DOI 10.1056/NEJMoa2101643
  17. Guyatt G, 2011, J CLIN EPIDEMIOL, V64, P383, DOI 10.1016/j.jclinepi.2010.04.026
  18. hcor, COALIZAO COVID BRASI
  19. Janssen Research & Development LLC, 2021, STUD RIV RED RISK MA
  20. Kalil AC, 2020, JAMA-J AM MED ASSOC, V323, P1897, DOI 10.1001/jama.2020.4742
  21. Klimek L, 2021, HNO, V69, P35, DOI 10.1007/s00106-021-01070-9
  22. Lee K, 2009, GLOB INST, P1
  23. Lotfi T, 2021, J CLIN EPIDEMIOL, V135, P182, DOI 10.1016/j.jclinepi.2021.03.034
  24. Marconi VC, 2021, LANCET RESP MED, V9, P1407, DOI 10.1016/S2213-2600(21)00331-3
  25. Merck, INT AN 7 3 PERC PAT
  26. NIH, COVID 19 TREATM GUID
  27. pfizer.com, PFIZ NOV COVID 19 OR
  28. Recovery trial, US
  29. Reis G, 2022, LANCET GLOB HEALTH, V10, pE36, DOI 10.1016/S2214-109X(21)00448-4
  30. Schunemann HJ, 2014, CAN MED ASSOC J, V186, pE123, DOI 10.1503/cmaj.131237
  31. Schunemann H, GRADE HDB HDB GRADIN
  32. Schunemann HJ, 2017, J CLIN EPIDEMIOL, V81, P101, DOI 10.1016/j.jclinepi.2016.09.009
  33. Sciurba Frank C., 2021, COVID 19 POSITIVE OU
  34. Tanni SEB HA, 2021, WORLD MED J, V2, P37
  35. The National Institute for Health and Care Excellence (NICE) London, COVID 19 RAP GUID MA
  36. togethertrial, TOGHETER CLIN TRIALS
  37. who, WHO COVID 19 SOLIDAR

Coleções
Artigos e Materiais de Revistas Científicas - FM/MCP
Artigos e Materiais de Revistas Científicas - COVID-19
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - LIM/09
Artigos e Materiais de Revistas Científicas - LIM/48
Carregar mais